Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 381-386

  Sit, Dorothy ^a   Perel, James M ^a   Luther, James F ^a   Wisniewski, Stephen R ^a   Helsel, Joseph C ^a   Wisner, Katherine L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

depression level; fluoxetine; metabolism; postpartum; pregnancy; stereoisomers

Indexed keywords

FLUOXETINE; NORFLUOXETINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CHIRALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HUMAN; PREGNANCY; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RACEMIZATION; REMISSION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; PREGNANCY COMPLICATION; PSYCHOLOGICAL RATING SCALE; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STEREOISOMERISM; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PSYCHIATRIC STATUS RATING SCALES; STEREOISOMERISM;

EID: 77955139462     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e7be23     Document Type: Article

References (41)

1. Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Summary, Evidence Report/Technology Assessment No. AHRQ Publication No. 05-E006-1.
2. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. [Erratum appears in Obstet Gynecol. 2004 Jun;103(6):1344]. Obstet Gynecol. 2004;103(4): 698-709.
3. Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. New Engl J Med. 2006;354(20):2188-2190; author reply 2188-2190.
4. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73(4):330-337.
5. Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61(2):155-163.
6. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150(10):1541-1542.
7. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62(4):400-407.
8. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 1997;7(1):1-10.
9. Tracy TS, Venkataramanan R, Glover DD, et al. National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633-639.
10. Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. [see comment]. J Clin Psychiatry. 2008;69(4):652-658.
11. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27(7):763-766.
12. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11(2):51-57.
13. Freeman MP, Nolan PE Jr, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28(6):646-653.
14. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes mediating sertraline biotransformation: seeking attribution [Editorial]. J Clin Psychopharmacol. 1999;19:489-493.
15. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339-346.
16. Nakai A, Sekiya I, Oya A, et al. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet. 2002;266(1):25-29.
17. Keller F, Griesshammer M, Haussler U, et al. Pregnancy and renal failure: the case for application of dosage guidelines. Drugs. 2001;61(13):1901-1920.
18. Weinstein M. Lithium Treatment of Women During Pregnancy and in the Post-delivery Period. Lancaster, England: MTP Press; 1980.
19. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10): 989-1008.
20. Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296-301.
21. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol. 2001;21(3):330-334.
22. Margolis JM, O'Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28(10):1187-1191.
23. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology. 1997;132(4):402-407.
24. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9(1):55-60.
25. Ring BJ, Eckstein JA, Gillespie JS, et al. Identification of the human cytochromes p450 responsible for in vitro formation of R-and S-norfluoxetine. J Pharmacol Exp Ther. 2001;297(3):1044-1050.
26. Henry ME, Schmidt ME, Hennen J, et al. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology. 2005;30(8): 1576-1583.
27. Wong DT, Bymaster FP, Reid LR, et al. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology. 1993;8(4):337-344.
28. Fuller RW, Snoddy HD, Krushinski JH, et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992;31(10):997-1000.
29. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit. 2001;23(2):139-147.
30. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21(2):161-166.
31. Jannuzzi G, Gatti G, Magni P, et al. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit. 2002;24(5):616-627.
32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I DisordersVPatient Edition. Washington, D.C.: American Psychiatric Press; 1996.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
34. Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry. 1988;145(7):844-848.
35. Piperaki S, Parissi-Poulou M. Use of cyclodextrins as chiral selectors for direct resolution of the enantiomers of fluoxetine and its metabolite norfluoxetine by HPLC. Chirality. 1993;5:258-266. DOI: 10.1002/chir.530050414.
36. Shemesh E, Shneider BL, Savitzky JK, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics. 2004;113(4):825-832.
37. Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48(10):677-683.
38. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996;60(5):512-521.
39. Goldstein DB, Need AC, Singh R, et al. Potential genetic causes of heterogeneity of treatment effects. Am J Med. 2007; 120(4 suppl 1):S21-S25.
40. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. Jo Clin Psychopharmacol. 1991;11(3):224-225.
41. Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997;33(2):243-248.